Supplementary Table 1. First line chemotherapy regimen in the study patients according to the treatment group

|  |  |
| --- | --- |
| **Chemotherapy alone group** | n =891 (%) |
| FOLFIRI | 354 (40%) |
| FOLFOX | 305 (34%) |
| SOX | 25 (2.8%) |
| XELOX | 207 (23%) |
| **Chemotherapy + anti-VEGF antibody** | n = 266 (%) |
| Bevacizumab + FOLFIRI | 181 (68%) |
| Bevacizumab + FOLFOX | 85 (32%) |
| **Chemotherapy + anti-EGFR antibody** | n = 104 (%) |
| Cetuximab + FOLFIRI  | 86 (83%) |
| Cetuximab + FOLFOX  | 18 (17%) |

Abbreviations; FOLFIRI, Folinic acid, fluorouracil, and irinotecan; FOLFOX, Folinic acid, fluorouracil, and oxaliplatin; SOX, S-1 and oxaliplatin; XELOX, capecitabine, and oxaliplatin.